These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 10832612

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
    Trapella C, Fischetti C, Pela' M, Lazzari I, Guerrini R, Calo' G, Rizzi A, Camarda V, Lambert DG, McDonald J, Regoli D, Salvadori S.
    Bioorg Med Chem; 2009 Jul 15; 17(14):5080-95. PubMed ID: 19527931
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
    Tzschentke TM, Rutten K.
    Neuropharmacology; 2018 Feb 15; 129():100-108. PubMed ID: 29155273
    [Abstract] [Full Text] [Related]

  • 26. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
    Peng YL, Chang M, Dong SL, Li W, Han RW, Fu GX, Chen Q, Wang R.
    Regul Pept; 2006 May 15; 134(2-3):75-81. PubMed ID: 16516988
    [Abstract] [Full Text] [Related]

  • 27. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist.
    Trapella C, Guerrini R, Piccagli L, Calo' G, Carra' G, Spagnolo B, Rubini S, Fanton G, Hebbes C, McDonald J, Lambert DG, Regoli D, Salvadori S.
    Bioorg Med Chem; 2006 Feb 01; 14(3):692-704. PubMed ID: 16202610
    [Abstract] [Full Text] [Related]

  • 28. Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.
    Fischetti C, Rizzi A, Gavioli EC, Marzola G, Trapella C, Guerrini R, Petersen JS, Calo G.
    Peptides; 2009 Feb 01; 30(2):248-55. PubMed ID: 18992780
    [Abstract] [Full Text] [Related]

  • 29. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.
    Bigoni R, Giuliani S, Calo' G, Rizzi A, Guerrini R, Salvadori S, Regoli D, Maggi CA.
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar 01; 359(3):160-7. PubMed ID: 10208302
    [Abstract] [Full Text] [Related]

  • 30. [Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor.
    Butour JL, Moisand C, Mollereau C, Meunier JC.
    Eur J Pharmacol; 1998 May 15; 349(1):R5-6. PubMed ID: 9669489
    [Abstract] [Full Text] [Related]

  • 31. Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.
    McDonald J, Barnes TA, Calo G, Guerrini R, Rowbotham DJ, Lambert DG.
    Eur J Pharmacol; 2002 May 17; 443(1-3):7-12. PubMed ID: 12044785
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.
    Flau K, Redmer A, Liedtke S, Kathmann M, Schlicker E.
    Br J Pharmacol; 2002 Dec 17; 137(8):1355-61. PubMed ID: 12466246
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites.
    Nicholson JR, Paterson SJ, Menzies JR, Corbett AD, McKnight AT.
    Can J Physiol Pharmacol; 1998 Mar 17; 76(3):304-13. PubMed ID: 9673794
    [Abstract] [Full Text] [Related]

  • 34. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin.
    Calò G, Rizzi A, Bogoni G, Neugebauer V, Salvadori S, Guerrini R, Bianchi C, Regoli D.
    Eur J Pharmacol; 1996 Sep 05; 311(1):R3-5. PubMed ID: 8884244
    [Abstract] [Full Text] [Related]

  • 35. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
    Chiou LC, Fan SH, Chuang KC, Liao YY, Lee SZ.
    Ann N Y Acad Sci; 2004 Oct 05; 1025():398-403. PubMed ID: 15542742
    [Abstract] [Full Text] [Related]

  • 36. Orphanin FQ has an inhibitory effect on the guinea pig ileum and the mouse vas deferens.
    Zhang G, Murray TF, Grandy DK.
    Brain Res; 1997 Oct 24; 772(1-2):102-6. PubMed ID: 9406961
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.
    James MK, Feldman PL, Schuster SV, Bilotta JM, Brackeen MF, Leighton HJ.
    J Pharmacol Exp Ther; 1991 Nov 24; 259(2):712-8. PubMed ID: 1658308
    [Abstract] [Full Text] [Related]

  • 39. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
    Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV, Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C, Zaveri NT, Calo G.
    Eur J Pharmacol; 2016 Dec 15; 793():1-13. PubMed ID: 27780725
    [Abstract] [Full Text] [Related]

  • 40. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors.
    Hawkinson JE, Acosta-Burruel M, Espitia SA.
    Eur J Pharmacol; 2000 Feb 18; 389(2-3):107-14. PubMed ID: 10688973
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.